Skip to content
COVID19, Medical Health Aged Care

Chronic fatigue condition offers clues to Long COVID

La Trobe University 2 mins read

New research by La Trobe University has uncovered the intricate relationship between two debilitating conditions, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID; offering insights into disease pathologies and potential treatment avenues.

The review article, Unravelling shared mechanisms: insights from recent ME/CFS research to illuminate long COVID pathologies, studied both diseases in tandem to unlock a deeper understanding of their shared characteristics and unique molecular abnormalities.

Lead author Dr Sarah Annesley, Head of La Trobe’s Molecular Cell Biology Laboratory, investigated the disease pathologies which highlighted the significant overlap between the two conditions, with approximately half of Long COVID patients meeting the diagnostic criteria for ME/CFS.

“Research into both disorders is mutually beneficial as Long COVID can provide a unique opportunity to study early disease changes and map these changes over the duration of the disease,” Dr Annesley said.

“Conversely the ME/CFS research, which typically involves patients with a longer disease duration, may provide clues as to the future disease pathology of Long COVID.”

While the two conditions share clinical similarities and proposed disease pathologies, it remains unclear if they also share common molecular abnormalities.

“Most consistently altered pathologies in ME/CFS and Long COVID include an increased reliance on alternatives to carbohydrates as substrates for energy production and altered gut microbiota, with a reduction in butyrate-synthesising bacteria,” Dr Annesley said.

The review highlighted promising early results in therapeutic interventions targeting autoimmune responses in ME/CFS and Long COVID, which will require further clinical trials.

The research identified potential signs in the body, known as biomarkers, which could help doctors diagnose and track these conditions better. It was found measuring certain types of RNA could be the most accurate and clinically practicable clues for ME/CFS. However, their accuracy and clinical use require replication and validation in larger samples.

“Leveraging insights into both disorders may accelerate progress towards improving the lives of people affected by these debilitating conditions,” Dr Annesley said.

Dr Annesley’s paper coincides with the announcement of two La Trobe ME projects which have been awarded grants to conduct further studies into the condition, including one with Dr Annesley as an investigator. This project will examine how the different pathologies of ME/CFS and Long COVID interact, such as alterations in the gut, microbiota, the immune system and metabolism.

Link to paper here.

Media Contact
Jess Whitty - j.whitty@latrobe.edu.au, 0481 383 817

 

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.